When all the data were combined, the mTOR rs2295080 SNP appeared to be modestly protective and significantly associated with a decreased cancer risk under most of the genetic models tested without obvious among-study heterogeneity (homozygous: OR = 0.79, 95% CI = 0.66–0.95; heterozygous: OR = 0.88, 95% CI = 0.78–1.02, dominant: OR = 0.87, 95% CI = 0.80–0.94, recessive: OR = 0.82, 95% CI = 0.69–0.90) (Figure 1). Here, MTOR is linked to cancer.